Results 91 to 100 of about 462 (190)

Ruinism pre-IA on Art History

Estudio de los precedentes del tema del Ruinismo previo a las reconstrucciones y recreaciones mediante la IAStudy of the precedents of the subject of Ruinism previous to reconstructions and recreations using AIDepto. de Historia del ArteFac. de Geografía
Merino Peral, Esther, Blázquez Mateos, Eduardo   +1 more
core   +1 more source

Multi-Institution Analysis of Tarlatamab for the Treatment of <i>EGFR</i>-Mutant Transformed Small Cell Lung Cancer. [PDF]

JCO Precis Oncol
Cooper AJ, Herzberg B, Parma M, Wang K, Alder L, Weber UM, Patil T, Joshi U, Puri S, Saqi A, Clark P, Gay CM, Cascone T, Singhi EK, Blumenschein G, Skoulidis F, Tu J, Stinchcombe TE, Rudin CM, Shu CA, Byers LA, Yu H, Zhang B.   +22 more
europepmc   +1 more source

First-in-human study of the dual A₂_A/A₂_B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors. [PDF]

ESMO Open
Siu LL, Gutierrez ME, Pudelko L, Ruth K, Filho MAFN, Zaynagetdinov R, Hu P, Kitzing T, Guenhan BK, Durutovic I, McKean M.   +10 more
europepmc   +1 more source

Estudio de los corales con aulos del Viseense (Carbonífero ) de la Unidad de la Sierra del Castillo (Área del Guadiato, SO de España).

, 2001
Se describen los corales rugosos con aulos del Viseense del Área del Guadiato (Ossa-Morena). Los corales proceden de las localidades de Sierra del Castillo (secciones del Collado y la Cantera), Sierra de la Estrella (ambas en el término de Espiel) y de ...
Rodríguez, Sergio, Said, Ismail, Hernando Hernando, José Miguel, Hernando, José Miguel, Rodríguez García, Sergio   +4 more
core  

Crossing the finish line towards a disease-modifying treatment for Angelman syndrome. [PDF]

J Neurodev Disord
Judson MC, de Almeida LP, Burdine RD, Chamberlain SJ, Deverman BE, Distel B, Ehlers MD, Jalazo E, Kushner SA, Nespeca M, Sanders SJ, Scheffner M, Yi JJ, Zylka MJ, Elgersma Y, Philpot BD.   +15 more
europepmc   +1 more source

A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours. [PDF]

Br J Cancer, 2023
Desai J, Fong P, Moreno V, Frentzas S, Meniawy T, Markman B, Voskoboynik M, Rahman T, Budha N, Wu J, Marlow J, Yang S, Calvo E, Martin-Liberal J.   +13 more
europepmc   +1 more source

PD-1 Targeted Antibody Discovery Using AI Protein Diffusion. [PDF]

Technol Cancer Res Treat
Ford CT.
europepmc   +1 more source

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial. [PDF]

Br J Cancer, 2023
Friedlander M, Mileshkin L, Lombard J, Frentzas S, Gao B, Wilson M, Meniawy T, Baron-Hay S, Briscoe K, McCarthy N, Fountzilas C, Cervantes A, Ge R, Wu J, Spira A.   +14 more
europepmc   +1 more source

First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors. [PDF]

ESMO Open
Naing A, McKean M, Rosen LS, Sommerhalder D, Shaik NM, Wang IM, Le Corre C, Kern KA, Mishra NH, Pal SK.   +9 more
europepmc   +1 more source

Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial. [PDF]

Nat Cancer
Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE, Wada DA, Plaza JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Chmielowski B, Khushalani NI, Markowitz J, Monroe M, Contreras CM, Bowles T, Norman K, Medina E, Gonzalez CR, Baselga-Carretero I, Garcilazo IP, Vega-Crespo A, Chen JM, Deen NNA, Patel SP, Grossmann KF, Sondak VK, Sharon E, Moon J, Wu MC, Ribas A.   +32 more
europepmc   +1 more source